As a result, six BRCA2 variants, which VAFs ranged from 43.7 to 60.0% in ctDNA testing, were confirmed to be germline in patients with pancreatic (n = 2), breast (n = 2), ovarian (n = 1), and prostate cancers (n = 1) (Fig. 3 and Table 2). This evidence concerns the gene BRCA2 and prostate cancer.